ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v17i4.2160ppharm-1885Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWРоль эмолентов в предотвращении развития аллергических заболеваний на фоне атопического дерматита у детейRole of Emollients in Prevention of the Comorbid Allergic Diseases Development in Children with Atopic Dermatitishttps://orcid.org/0000-0003-2252-8570МурашкинН. Н.MurashkinNikolay N.

Мурашкин Николай Николаевич, доктор медицинских наук, заведующий отделением дерматологии с группой лазерной хирургии, заведующий лабораторией патологии кожи у детей отдела научных исследований в педиатрии НМИЦ здоровья детей, профессор кафедры дерматовенерологии и косметологии ЦГМА, профессор кафедры педиатрии и детской ревматологии Первого МГМУ им. И.М. Сеченова, заведующий отделом детской дерматологии НИИ педиатрии и охраны здоровья детей ЦКБ РАН

119296, Москва, Ломоносовский пр-т, д. 2, стр. 1

тел.: +7 (495) 967-14-20

m_nn2001@mail.ruhttps://orcid.org/0000-0002-0081-0981ИвановР. А.IvanovRoman A.https://orcid.org/0000-0001-9777-0156ФёдоровД. В.FedorovDmitri V.https://orcid.org/0000-0002-8232-8936АмбарчянЭ. Т.AmbarchyanEduard T.https://orcid.org/0000-0002-4107-4642ЕпишевР. В.EpishevRoman V.https://orcid.org/0000-0002-6034-8231МатерикинА. И.MaterikinAlexander I.https://orcid.org/0000-0002-0858-8780ОпрятинЛ. А.OpryatinLeonid A.https://orcid.org/0000-0001-6884-5171СавеловаА. А.SavelovaAlena A.Национальный медицинский исследовательский центр здоровья детей; Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет); Центральная государственная медицинская академия Управления делами Президента Российской Федерации; НИИ педиатрии и охраны здоровья детей ЦКБ РАНРоссияNational Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University; Central State Medical Academy of Department of Presidential Affairs; Research Institute of Pediatrics and Children’s Health in «Central Clinical Hospital of the Russian Academy of Sciences»Russian FederationНациональный медицинский исследовательский центр здоровья детейРоссияNational Medical Research Center of Children’s HealthRussian Federation202022092020174334339Copyright © Мурашкин Н.Н., Иванов Р.А., Фёдоров Д.В., Амбарчян Э.Т., Епишев Р.В., Материкин А.И., Опрятин Л.А., Савелова А.А., 20202020Мурашкин Н.Н., Иванов Р.А., Фёдоров Д.В., Амбарчян Э.Т., Епишев Р.В., Материкин А.И., Опрятин Л.А., Савелова А.А.Murashkin N.N., Ivanov R.A., Fedorov D.V., Ambarchyan E.T., Epishev R.V., Materikin A.I., Opryatin L.A., Savelova A.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/1885

Атопический дерматит (АтД) — одно из наиболее распространенных воспалительных заболеваний мультифакторной природы, проявляющихся преимущественно в детском возрасте. Несмотря на значительный процент случаев самостоятельного регресса болезни с возрастом, в ряде наблюдений демонстрируется иной сценарий развития событий, заканчивающийся персистентным течением АтД и/или формированием на его фоне сопутствующих аллергических патологий, что значительно ухудшает качество жизни пациента и приводит к его социальной дезадаптации. Патогенетическая основа такого пути состоит непосредственно в нарушении эпидермального барьера, формировании транскутанной сенсибилизации и развитии аберрантного аллергического (Th2-) иммунного системного ответа. При этом основная роль в предотвращении данного патологического пути отводится новому классу увлажняющих средств, содержащих в своем составе активные действующие компоненты, — «эмолентам плюс», считающимся краеугольным камнем в терапии и профилактике развития АтД и других аллергических заболеваний. В представленном обзоре литературы приводятся современные данные, касающиеся аспектов патогенеза АтД и развития на его фоне аллергических болезней. Также в работе рассматриваются данные о влиянии эмолентов на восстановление эпидермального барьера и возможностях их использования в качестве профилактических средств.

Atopic dermatitis (AD) is one of the common multifactorial inflammatory diseases manifesting predominantly in childhood. There is significant number of cases of self-regression of the disease with aging. On the other hand, there is also another scenario ending with AD persistent course and/or development of comorbid allergic pathologies that can significantly worsen patient’s quality of life and finally lead to social maladjustment. The pathogenesis of such way includes epidermal barrier disturbance, transcutaneous sensibilisation and aberrant allergic (Th2) immune systemic response development. Main role in preventing of this pathological pathway is lying on the new class of moisturizers containing active components "emollients plus". They are considered as foundation for the therapy and prevention of the development of AD and other allergic diseases. This literature review provides relevant data on AD pathogenesis and development of comorbid allergic pathologies. This paper also covers data on the effect of emollients in restoration of the epidermal barrier and their use as preventive measures.

атопический дерматитэпидермальный барьератопический маршэмолентыatopic dermatitisepidermal barrieratopic marchemollientsСтатья опубликована при поддержке компании Pierre Fabre.The article has been supported by Pierre Fabre LLC.ReferencesMcPherson T. Current Understanding in Pathogenesis of Atopic Dermatitis. Indian J Dermatol. 2016;61(6):649–655. doi: 10.4103/0019-5154.193674.McPherson T. Current Understanding in Pathogenesis of Atopic Dermatitis. Indian J Dermatol. 2016;61(6):649–655. doi: 10.4103/0019-5154.193674.Pyun BY. Natural history and risk factors of atopic dermatitis in children. Allergy Asthma Immunol Res. 2015;7(2):101–105. doi: 10.4168/aair.2015.7.2.101.Pyun BY. Natural history and risk factors of atopic dermatitis in children. Allergy Asthma Immunol Res. 2015;7(2):101–105. doi: 10.4168/aair.2015.7.2.101.Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010;105(2):99–106. doi: 10.1016/j.anai.2009.10.002.Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010;105(2):99–106. doi: 10.1016/j.anai.2009.10.002.Jianu E, Ulmeanu R. Links between allergic rhinitis and asthma. Romanian Journal of Rhinology. 2013;3(9):39–44.Jianu E, Ulmeanu R. Links between allergic rhinitis and asthma. Romanian Journal of Rhinology. 2013;3(9):39–44.Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient-burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018; 121(3):340–347. doi: 10.1016/j.anai.2018.07.006.Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient-burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018; 121(3):340–347. doi: 10.1016/j.anai.2018.07.006.Spergel J. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6):S118–S127. doi: 10.1016/j.jaci.2003.09.033.Spergel J. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6):S118–S127. doi: 10.1016/j.jaci.2003.09.033.Намазова-Баранова Л.С., Баранов А.А., Кубанова А.А. и др. Атопический дерматит у детей: современные клинические рекомендации по диагностике и терапии. Вопросы современной педиатрии. 2016;15(3):279–294. doi: 10.15690/vsp.v15i3.1566.Namazova-Baranova LS, Baranov AA, Kubanova AA, et al. Atopic Dermatitis in Children: Current Clinical Guidelines for Diagnosis and Therapy. Voprosy sovremennoi pediatrii — Current Pediatrics. 2016;15(3):279–294. doi: 10.15690/vsp.v15i3.1566.Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998;351(9111):1225–1232.Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998;351(9111):1225–1232.Pols DHJ, Wartna JB, Moed H, et al. Atopic dermatitis, asthma and allergic rhinitis in general practice and the open population: a systematic review. Scand J Prim Health Care. 2016;34(2): 143–150. doi: 10.3109/02813432.2016.1160629.Pols DHJ, Wartna JB, Moed H, et al. Atopic dermatitis, asthma and allergic rhinitis in general practice and the open population: a systematic review. Scand J Prim Health Care. 2016;34(2): 143–150. doi: 10.3109/02813432.2016.1160629.Kijima A, Murota H, Takahashi A, et al. Prevalence and Impact of Past History of Food Allergy in Atopic Dermatitis. Allergol Int. 2013;62(1):105–112. doi:10.2332/allergolint.12-oa-0468.Kijima A, Murota H, Takahashi A, et al. Prevalence and Impact of Past History of Food Allergy in Atopic Dermatitis. Allergol Int. 2013;62(1):105–112. doi:10.2332/allergolint.12-oa-0468.Dhar S, Srinivas SM. Food Allergy in Atopic Dermatitis. Indian J Dermatol. 2016;61(6):645–648. doi: 10.4103/0019-5154.193673.Dhar S, Srinivas SM. Food Allergy in Atopic Dermatitis. Indian J Dermatol. 2016;61(6):645–648. doi: 10.4103/0019-5154.193673.Rhodes HL, Sporik R, Thomas P, et al. Early life risk factors for adult asthma: a birth cohort study of subjects at risk. J Allergy Clin Immunol. 2001;108(5):720–725. doi: 10.1067/mai.2001.119151.Rhodes HL, Sporik R, Thomas P, et al. Early life risk factors for adult asthma: a birth cohort study of subjects at risk. J Allergy Clin Immunol. 2001;108(5):720–725. doi: 10.1067/mai.2001.119151.Celakovska J, Bukac J. Analysis of food allergy in atopic dermatitis patients — association with concomitant allergic diseases. Indian J Dermatol. 2014;59(5):445–450. doi: 10.4103/0019-5154.139867.Celakovska J, Bukac J. Analysis of food allergy in atopic dermatitis patients — association with concomitant allergic diseases. Indian J Dermatol. 2014;59(5):445–450. doi: 10.4103/0019-5154.139867.Pols DHJ, Wartna JB, van Alphen EI, et al. Interrelationships between Atopic Disorders in Children: A Meta-Analysis Based on ISAAC Questionnaires. PloS One. 20152;10(7):e0131869. doi: 10.1371/journal.pone.0131869.Pols DHJ, Wartna JB, van Alphen EI, et al. Interrelationships between Atopic Disorders in Children: A Meta-Analysis Based on ISAAC Questionnaires. PloS One. 20152;10(7):e0131869. doi: 10.1371/journal.pone.0131869.Lau S, Nickel R, Niggemann B, et al. The development of child-hood asthma: lessons from the German Multicentre Allergy Study (MAS). Paediatr Respir Rev. 2002;3(3):265–272. doi: 10.1016/s1526-0542(02)00189-6.Lau S, Nickel R, Niggemann B, et al. The development of child-hood asthma: lessons from the German Multicentre Allergy Study (MAS). Paediatr Respir Rev. 2002;3(3):265–272. doi: 10.1016/s1526-0542(02)00189-6.Kulig M, Bergmann R, Klettke U, et al. Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J Allergy Clin Immunol. 1999;103(6):1173–1179. doi: 10.1016/s0091-6749(99)70195-8.Kulig M, Bergmann R, Klettke U, et al. Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J Allergy Clin Immunol. 1999;103(6):1173–1179. doi: 10.1016/s0091-6749(99)70195-8.Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019;40(2):84–92. doi: 10.2500/aap.2019.40.4202.Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019;40(2):84–92. doi: 10.2500/aap.2019.40.4202.Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Opin Allergy Clin Immunol. 2009; 9(5):437–446. doi: 10.1097/ACI.0b013e32832e7d36.Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Opin Allergy Clin Immunol. 2009; 9(5):437–446. doi: 10.1097/ACI.0b013e32832e7d36.Yang G, Seok JK, Kang HC, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020;21(8):2867. doi: 10.3390/ijms21082867.Yang G, Seok JK, Kang HC, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020;21(8):2867. doi: 10.3390/ijms21082867.Elias PM, Steinhoff M. “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008;128(5):1067–1070. doi: 10.1038/jid.2008.88.Elias PM, Steinhoff M. “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008;128(5):1067–1070. doi: 10.1038/jid.2008.88.Wang YH, Liu YJ. OX40-OX40L interactions: a promising therapeutic target for allergic diseases? J Clin Invest. 2007;117(12): 3655–3657. doi: 10.1172/JCI34182.Wang YH, Liu YJ. OX40-OX40L interactions: a promising therapeutic target for allergic diseases? J Clin Invest. 2007;117(12): 3655–3657. doi: 10.1172/JCI34182.Biedermann T, Skabytska Y, Kaesler S, Volz T. Regulation of T Cell Immunity in Atopic Dermatitis by Microbes: The Yin and Yang of Cutaneous Inflammation. Front Immunol. 2015;6:353. doi: 10.3389/fimmu.2015.00353.Biedermann T, Skabytska Y, Kaesler S, Volz T. Regulation of T Cell Immunity in Atopic Dermatitis by Microbes: The Yin and Yang of Cutaneous Inflammation. Front Immunol. 2015;6:353. doi: 10.3389/fimmu.2015.00353.Elias PM, Feingold KR. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol. 2001;137(8):1079–1081.Elias PM, Feingold KR. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol. 2001;137(8):1079–1081.Мурашкин Н.Н., Иванов Р.А., Савелова А.А. и др. Роль эпидермального барьера в формировании пищевой аллергии у детей с генодерматозами. Педиатрическая фармакология. — 2019. — Т. 16. — № 4. — С. 234–240. doi: 10.15690/pf.v16i4.2053.Murashkin NN, Ivanov RA, Savelova AA, et al. Role of the Epidermal Barrier in the Formation of Food Allergies in Children with Genodermatosis. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2019;16(4):234–240. doi: 10.15690/pf.v16i4.2053.McAleer MA, Pohler E, Smith FJD, et al. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. J Allergy Clin Immunol. 2015;136(5):1268–1276. doi: 10.1016/j.jaci.2015.05.002.McAleer MA, Pohler E, Smith FJD, et al. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. J Allergy Clin Immunol. 2015;136(5):1268–1276. doi: 10.1016/j.jaci.2015.05.002.Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immu nol. 2007;120(1):150–155. doi: 10.1016/j.jaci.2007.04.031.Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immu nol. 2007;120(1):150–155. doi: 10.1016/j.jaci.2007.04.031.Kobayashi J, Inai T, Morita K, et al. Reciprocal regulation of permeability through a cultured keratinocyte sheet by IFN-gamma and IL-4. Cytokine. 2004;28(4–5):186–189. doi: 10.1016/j.cyto.2004.08.003.Kobayashi J, Inai T, Morita K, et al. Reciprocal regulation of permeability through a cultured keratinocyte sheet by IFN-gamma and IL-4. Cytokine. 2004;28(4–5):186–189. doi: 10.1016/j.cyto.2004.08.003.Hatano Y, Terashi H, Arakawa S, Katagiri K. Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factoralpha and interferon-gamma in human epidermis. J Invest Dermatol. 2005;124(4):786–792. doi: 10.1111/j.0022-202X.2005.23651.x.Hatano Y, Terashi H, Arakawa S, Katagiri K. Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factoralpha and interferon-gamma in human epidermis. J Invest Dermatol. 2005;124(4):786–792. doi: 10.1111/j.0022-202X.2005.23651.x.Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–417. doi: 10.1016/j.jaci.2005.10.033.Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–417. doi: 10.1016/j.jaci.2005.10.033.Wehner J, Neuber K. Staphylococcus aureus enterotoxins induce histamine and leukotriene release in patients with atopic eczema. Br J Dermatol. 2001;145(2):302–305. doi: 10.1046/j.1365-2133.2001.04352.x.Wehner J, Neuber K. Staphylococcus aureus enterotoxins induce histamine and leukotriene release in patients with atopic eczema. Br J Dermatol. 2001;145(2):302–305. doi: 10.1046/j.1365-2133.2001.04352.x.Turner MJ, Zhou B. A new itch to scratch for TSLP. Trends Immunol. 2014;35(2):49–50. doi: 10.1016/j.it.2013.12.001.Turner MJ, Zhou B. A new itch to scratch for TSLP. Trends Immunol. 2014;35(2):49–50. doi: 10.1016/j.it.2013.12.001.Rinaldi G. The Itch-Scratch Cycle: A Review of the Mecha nisms. Dermatol Pract Concept. 2019;9(2):90–97. doi: 10.5826/dpc.0902a03.Rinaldi G. The Itch-Scratch Cycle: A Review of the Mecha nisms. Dermatol Pract Concept. 2019;9(2):90–97. doi: 10.5826/dpc.0902a03.Murota H, Katayama I. Exacerbating factors of itch in atopic dermatitis. Allergol Int. 2017;66(1):8–13. doi: 10.1016/j.alit.2016.10.005.Murota H, Katayama I. Exacerbating factors of itch in atopic dermatitis. Allergol Int. 2017;66(1):8–13. doi: 10.1016/j.alit.2016.10.005.Feld M, Garcia R, Buddenkotte J, et al. The pruritusand TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol. 2016;138(2):500–508.e24. doi: 10.1016/j.jaci.2016.02.020.Feld M, Garcia R, Buddenkotte J, et al. The pruritusand TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol. 2016;138(2):500–508.e24. doi: 10.1016/j.jaci.2016.02.020.Kondo H, Ichikawa Y, Imokawa G. Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. Eur J Immunol. 1998;28(3):769–779. doi: 10.1002/(SICI)1521-4141(199803)28:03<769::AID-IMMU769>3.0.CO;2-H.Kondo H, Ichikawa Y, Imokawa G. Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. Eur J Immunol. 1998;28(3):769–779. doi: 10.1002/(SICI)1521-4141(199803)28:03<769::AID-IMMU769>3.0.CO;2-H.Lowe AJ, Leung DYM, Tang MLK, et al. The skin as a target for prevention of the atopic march. Ann Allergy Asthma Immunol. 2018;120(2):145–151. doi: 10.1016/j.anai.2017.11.023.Lowe AJ, Leung DYM, Tang MLK, et al. The skin as a target for prevention of the atopic march. Ann Allergy Asthma Immunol. 2018;120(2):145–151. doi: 10.1016/j.anai.2017.11.023.Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J Clin Invest. 2012;122(2):440–447. doi: 10.1172/JCI57416.Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J Clin Invest. 2012;122(2):440–447. doi: 10.1172/JCI57416.Schafer T, Heinrich J, Wjst M, et al. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol. 1999;104(6):1280–1284. doi: 10.1016/s0091-6749(99)70025-4.Schafer T, Heinrich J, Wjst M, et al. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol. 1999;104(6):1280–1284. doi: 10.1016/s0091-6749(99)70025-4.De Benedetto A, Kubo A, Beck LA. Skin Barrier Disruption: A Requirement for Allergen Sensitization? J Invest Dermatol. 2012; 132(3):949–963. doi: 10.1038/jid.2011.435.De Benedetto A, Kubo A, Beck LA. Skin Barrier Disruption: A Requirement for Allergen Sensitization? J Invest Dermatol. 2012; 132(3):949–963. doi: 10.1038/jid.2011.435.Izadi N, Luu M, Ong PY, Tam JS. The Role of Skin Barrier in the Pathogenesis of Food Allergy. Children (Basel). 2015;2(3):382–402. doi: 10.3390/children2030382.Izadi N, Luu M, Ong PY, Tam JS. The Role of Skin Barrier in the Pathogenesis of Food Allergy. Children (Basel). 2015;2(3):382–402. doi: 10.3390/children2030382.Chin S, Vickery BP. Pathogenesis of food allergy in the pediatric patient. Curr Allergy Asthma Rep. 2012;12(6):621–629. doi: 10.1007/s11882-012-0296-x.Chin S, Vickery BP. Pathogenesis of food allergy in the pediatric patient. Curr Allergy Asthma Rep. 2012;12(6):621–629. doi: 10.1007/s11882-012-0296-x.Furue M, Chiba T, Tsuji G, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017;66(3):398–403. doi: 10.1016/j.alit.2016.12.002.Furue M, Chiba T, Tsuji G, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017;66(3):398–403. doi: 10.1016/j.alit.2016.12.002.Zhang Y, Zhou B. Functions of thymic stromal lymphopoietin in immunity and disease. Immunol Res. 2012;52(3):211–223. doi: 10.1007/s12026-012-8264-z.Zhang Y, Zhou B. Functions of thymic stromal lymphopoietin in immunity and disease. Immunol Res. 2012;52(3):211–223. doi: 10.1007/s12026-012-8264-z.Cianferoni A, Spergel J. The importance of TSLP in allergic disease and its role as a potential therapeutic target. Expert Rev Clin Immunol. 2014;10(11):1463–1474. doi: 10.1586/1744666X.2014.967684.Cianferoni A, Spergel J. The importance of TSLP in allergic disease and its role as a potential therapeutic target. Expert Rev Clin Immunol. 2014;10(11):1463–1474. doi: 10.1586/1744666X.2014.967684.Yoo J, Omori M, Gyarmati D, et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med. 2005;202(4):541–549. doi: 10.1084/jem.20041503.Yoo J, Omori M, Gyarmati D, et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med. 2005;202(4):541–549. doi: 10.1084/jem.20041503.Kjellman NI, Nilsson L. From food allergy and atopic dermatitis to respiratory allergy. Pediatr Allergy Immunol. 1998;9(11 Suppl):13–17.Kjellman NI, Nilsson L. From food allergy and atopic dermatitis to respiratory allergy. Pediatr Allergy Immunol. 1998;9(11 Suppl):13–17.Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587–593. doi: 10.1016/j.jaad.2009.11.011.Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587–593. doi: 10.1016/j.jaad.2009.11.011.Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. doi: 10.1016/j.jaad.2014.03.023.Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. doi: 10.1016/j.jaad.2014.03.023.Simpson EL. Atopic dermatitis: a review of topical treatment options. Cur Med Res Opin. 2010;26(3):633–640. doi: 10.1185/03007990903512156.Simpson EL. Atopic dermatitis: a review of topical treatment options. Cur Med Res Opin. 2010;26(3):633–640. doi: 10.1185/03007990903512156.van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017; 2(2):CD012119. doi: 10.1002/14651858.CD012119.pub2.van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017; 2(2):CD012119. doi: 10.1002/14651858.CD012119.pub2.Mack Correa CM, Nebus J. Management of patients with atopic dermatitis: the role of emollient therapy. Dermatol Res Pract. 2012;2012:836931. doi: 10.1155/2012/836931.Mack Correa CM, Nebus J. Management of patients with atopic dermatitis: the role of emollient therapy. Dermatol Res Pract. 2012;2012:836931. doi: 10.1155/2012/836931.Cork MJ, Danby S. Aqueous cream damages the skin barrier. Br J Derma tol. 2011;164(6):1179–1180. doi: 10.1111/j.1365-2133.2011.10390.x.Cork MJ, Danby S. Aqueous cream damages the skin barrier. Br J Derma tol. 2011;164(6):1179–1180. doi: 10.1111/j.1365-2133.2011.10390.x.Lowe AJ, Su JC, Allen KJ, et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. Br J Dermatol. 2017;178(1):e19–e21. doi: 10.1111/bjd.15747.Lowe AJ, Su JC, Allen KJ, et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. Br J Dermatol. 2017;178(1):e19–e21. doi: 10.1111/bjd.15747.Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891.Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891.Левина Ю.Г., Алексеева А.А., Эфендиева К.Е., Вишнёва Е.А., Намазова-Баранова Л.С. Коррекция дисбиоза кожи как неотъемлемая составная часть патогенетической терапии атопического дерматита. Педиатрическая фармакология . 2019; 16(2):97–100. doi: 10.15690/pf.v16i2.2006Левина Ю.Г., Алексеева А.А., Эфендиева К.Е., Вишнёва Е.А., Намазова-Баранова Л.С. Коррекция дисбиоза кожи как неотъемлемая составная часть патогенетической терапии атопического дерматита. Педиатрическая фармакология . 2019; 16(2):97–100. doi: 10.15690/pf.v16i2.2006Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387(10023):1109–1122. doi: 10.1016/s0140-6736(15)00149-x.Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387(10023):1109–1122. doi: 10.1016/s0140-6736(15)00149-x.Mandeau A, Aries M-F, Bieber T. et al. Rhealba Oat Plantlet Extract: Evidence of Protein-Free Content and Assessment of Regulatory Activity on Immune Inflammatory Mediators. Planta Med. 2011:77(09);900–906. doi: 10.1055/s-0030-1250649.Mandeau A, Aries M-F, Bieber T. et al. Rhealba Oat Plantlet Extract: Evidence of Protein-Free Content and Assessment of Regulatory Activity on Immune Inflammatory Mediators. Planta Med. 2011:77(09);900–906. doi: 10.1055/s-0030-1250649.Stalder JF, Tennstedt D, Deleuran M, et al. Fragility of epidermis and its consequence in dermatology. J Eur Acad Dermatol Venereol. 2014;28(Suppl 4):1–18. doi: 10.1111/jdv.12509.Stalder JF, Tennstedt D, Deleuran M, et al. Fragility of epidermis and its consequence in dermatology. J Eur Acad Dermatol Venereol. 2014;28(Suppl 4):1–18. doi: 10.1111/jdv.12509.Saint Aroman M, Guillot P, Dahan S, et al. Efficacy of a repair cream containing Rhealba oat plantlets extracts, L-ALA-L-GLU dipeptide, and hyaluronic acid in wound-healing following dermatological acts: a meta-analysis of >2,000 patients in eight countries corroborated by a dermatopediatric clinical case. Clin Cosmet Investig Dermatol. 2018;11:579–589. doi: 10.2147/CCID.S177614.Saint Aroman M, Guillot P, Dahan S, et al. Efficacy of a repair cream containing Rhealba oat plantlets extracts, L-ALA-L-GLU dipeptide, and hyaluronic acid in wound-healing following dermatological acts: a meta-analysis of >2,000 patients in eight countries corroborated by a dermatopediatric clinical case. Clin Cosmet Investig Dermatol. 2018;11:579–589. doi: 10.2147/CCID.S177614.Wollenberg A., Folster-Holst R, Saint Aroman M, et al. Effects of a protein-free oat plantlet extract on microinflammation and skin barrier function in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2018;32(Suppl 1):1–15. doi: 10.1111/jdv.14846.Wollenberg A., Folster-Holst R, Saint Aroman M, et al. Effects of a protein-free oat plantlet extract on microinflammation and skin barrier function in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2018;32(Suppl 1):1–15. doi: 10.1111/jdv.14846.Grimalt R, Mengeaud V, Cambazard F. The Steroid-Sparing Effect of an Emollient Therapy in Infants with Atopic Dermatitis: A Randomized Controlled Study. Dermatology. 2006;214(1):61–67. doi: 10.1159/000096915.Grimalt R, Mengeaud V, Cambazard F. The Steroid-Sparing Effect of an Emollient Therapy in Infants with Atopic Dermatitis: A Randomized Controlled Study. Dermatology. 2006;214(1):61–67. doi: 10.1159/000096915.Patel N, Feldman SR. Adherence in Atopic Dermatitis. In: Management of Atopic Dermatitis. Fortson EA, Feldman SR, Strowd LC, eds. Springer; 2017. pp. 139–159. doi: 10.1007/978-3-319-64804-0_12.Patel N, Feldman SR. Adherence in Atopic Dermatitis. In: Management of Atopic Dermatitis. Fortson EA, Feldman SR, Strowd LC, eds. Springer; 2017. pp. 139–159. doi: 10.1007/978-3-319-64804-0_12.

The authors declare that there are no conflicts of interest present.